TRIP13 and acute kidney injury: Since TRIP13 was detected in normal and AKI human kidney sections (Supplemental Figure 4) similar to our findings in mice (26), TRIP13 or its associated binding proteins may become potential therapeutic targets to protect the kidney from not only cisplatin nephrotoxicity but also possibly other forms of acute and chronic kidney disease.